By Sina Rezvan
Most digital pathology IMS platforms look similar in a demo.
Slides load. Cases open. Reports export. At first glance, the functionality appears comparable.
The differences emerge later when volume increases, sites expand, turnaround times tighten, or AI becomes part of daily workflow. That’s when architecture starts to matter.
Choosing a digital pathology IMS isn’t just about enabling digital sign-out. It’s about selecting infrastructure that will scale with your lab over the next three to five years.
The real question isn’t, “Does this platform work?” It’s, “Will it support growth, improve productivity, integrate cleanly, and deliver measurable return over time?”
Here’s what growing labs should prioritize.
Not All Digital Pathology IMS Platforms Are Built for Growth
At first glance, most digital pathology IMS platforms appear to solve the same problem: digitize slides, allow case review, and enable remote access. And technically, they do.
But growth changes the equation.
As volume increases, services expand, AI is introduced, multiple sites collaborate, or new labs are acquired – often with different LIS environments – the demands on your system evolve. What worked well for a single-site implementation can start to feel constrained when operational complexity increases.
The question isn’t whether a platform works today. It’s whether it continues to work as your lab scales.
Why Most Platforms Look Similar at First
In early evaluations, the visible features tend to dominate the conversation:
- Image quality and viewer performance
- Annotation tools
- Reporting integration
- Basic case management
In a controlled demo environment, most systems perform well. Slides load quickly. Navigation feels smooth. The core functionality checks the expected boxes.
As a result, many digital pathology IMS platforms feel interchangeable at first. The differences often don’t surface until the system is tested against real-world volume and workflow complexity.
Where Meaningful Differences Start to Appear
The differences become clear when you look beyond the demo and examine how the system performs under real operational demands.
Meaningful differences emerge around:
- Scalability: Can the infrastructure handle increasing volume without adding proportional cost or staff?
- Workflow orchestration: How are cases routed, prioritized, and balanced across pathologists and locations?
- AI readiness: Can you add multiple algorithms without restructuring your system?
- Interoperability: How easily does the platform integrate with your LIS, scanners, and enterprise systems?
- Long-term flexibility: Will this system still meet your needs in three to five years?
These are architectural considerations, not surface features. They directly affect productivity, cost structure, and future expansion.
When selecting a digital pathology IMS, the objective isn’t to choose the system that demos well, it’s to choose the one built to scale.
Workflow Orchestration, Not Just Image Viewing
A digital pathology IMS does more than display slides. It shapes how cases move through your lab.
In smaller or less complex environments, basic case access may be enough. But as volume grows or teams become distributed, the way cases are routed, prioritized, and tracked has a direct impact on turnaround time, pathologist productivity, and overall lab efficiency.
In larger health systems, enterprise labs, or multi-site environments, workflow orchestration becomes even more critical. Case distribution across subspecialties, load balancing between pathologists, STAT prioritization, and visibility into bottlenecks are not operational luxuries, they are essential to maintaining consistency and protecting turnaround times. Without intentional workflow architecture, complexity compounds quickly, and inefficiencies scale alongside volume.
This is where workflow design starts to matter.
Case Routing and Workload Balancing
In many labs, case assignment still relies on manual distribution, inbox-driven coordination, or informal rules. That works….until it doesn’t.
As subspecialties expand, sites multiply, or staffing shifts, routing becomes a control point for performance.
A growth-ready digital pathology IMS should support:
- Rules-based routing by subspecialty, case type, or priority
- Balanced distribution across pathologists
- Flexible reassignment without disrupting workflow
- Clear accountability at every stage
Structured routing reduces bottlenecks and prevents cases from sitting in the wrong queue.
Prioritization and Turnaround Time Management
Turnaround time depends on how efficiently cases move through the system — not just how quickly they are reviewed.
Without structured prioritization, urgent cases compete with routine work, and reprioritization can disrupt existing queues. Delays often aren’t visible until they affect performance.
An effective digital pathology IMS should enable you to:
- Flag and elevate priority cases
- Monitor queue status in real time
- Track turnaround time at both individual and system levels
- Identify bottlenecks early
When prioritization is built into the workflow, turnaround time becomes manageable, not reactive.
Visibility Across Teams and Locations
Growth often brings additional sites, remote coverage, subspecialty consults, or hybrid teams.
In these environments, visibility is essential. Teams need clarity on:
- Where a case stands
- Who is responsible
- What actions have been completed
A well-designed digital pathology IMS provides centralized visibility across roles and locations. That reduces status inquiries and manual follow-up while improving coordination and accountability.
As labs expand, the difference isn’t in how quickly slides load — it’s in how clearly the workflow is managed around them.
Pathologist Productivity and Throughput
As volume increases, pathologist time becomes the limiting factor. Most labs don’t struggle because slides can’t be viewed — they struggle because capacity is finite.
Extra clicks, manual reassignment, and coordination steps take time away from review. Individually they seem minor. Across dozens of cases per day, they reduce throughput.
When evaluating a digital pathology IMS, the question is straightforward:
Does this system meaningfully support the number of cases a pathologist needs to sign out each day?
Improving Sign-Out Efficiency
Pathologist time is one of the most limited resources in the lab.
A digital pathology IMS should support and streamline the number of cases each pathologist can review and sign out per day — without compromising accuracy.
That improvement comes from structured workflow, not simply digital access.
For example:
- Cases are pre-routed to the right subspecialist
- Urgent cases are clearly flagged
- Related slides and prior cases are immediately accessible
- Reassignments are simple and do not disrupt progress
- Case queues are organized and easy to digest
When workflow is structured this way, pathologists spend less time managing process and more time reviewing cases.
Even small time savings per case, applied consistently, translate into meaningful throughput gains.
Measuring Efficiency Gains
Productivity should be measurable.
An effective digital pathology IMS provides visibility into:
- Cases signed out per day
- Queue depth and aging
- Subspecialty workload distribution
These metrics show where efficiency is improving and where bottlenecks remain.
Without clear data, which can be accessed through management reports in the LIS, it’s difficult to know whether a system is increasing throughput or simply digitizing existing constraints.
Reducing Cognitive Load in High-Volume Environments
High-volume pathology labs require sustained focus. Repetitive benign cases, complex decisions, and constant task switching increase mental strain.
Digital workflow can either add to that burden or help manage it.
Structured case queues, and integrated assistive tools (including AI where appropriate) allow pathologists to concentrate on interpretation rather than process management.
Throughput isn’t just about speed. It’s about creating a system where pathologists can work efficiently and consistently as volume grows.
AI Integration and Future Readiness
AI is becoming part of the digital pathology conversation whether a lab plans to adopt it immediately or not. The question is how easily your digital pathology IMS can support it when you’re ready.
Future readiness is less about having AI today and more about ensuring your infrastructure won’t limit you tomorrow.
Multi-Algorithm Flexibility
AI in pathology isn’t a single tool. Different algorithms support screening, identification, quantification, grading, prioritization, and quality checks.
A growth-ready digital pathology IMS should allow you to:
- Integrate multiple algorithms over time
- Add new AI tools without restructuring your system
- Manage updates without disrupting workflow
AI capabilities will continue to evolve. A system limited to a single embedded solution may restrict your options as more specialized tools emerge.
Assistive AI and Diagnostic Confidence
AI should function as assistive infrastructure, not as a replacement for clinical judgment.
Used appropriately, AI can:
- Flag cases for prioritization
- Highlight areas of interest
- Standardize measurements
- Provide a secondary check for high-risk findings
When integrated thoughtfully, these capabilities can support diagnostic consistency and reduce variability, particularly in high-volume environments.
The goal isn’t to replace pathologists. It’s to reinforce accuracy and efficiency.
Avoiding Closed Ecosystems
As AI adoption expands, ecosystem design matters.
Some digital pathology IMS platforms operate within tightly controlled environments that limit which tools can be integrated. Others are built for flexibility, allowing labs to incorporate external or future AI solutions as needs evolve.
Selecting an open, adaptable architecture reduces the risk of replatforming and preserves control over how and when AI is introduced.
Future readiness isn’t about predicting specific tools. It’s about ensuring your digital pathology IMS can evolve with your lab.
Integration and Interoperability
A digital pathology IMS does not operate in isolation. It must align with your LIS, scanners, , and broader enterprise IT environment.
Integration often determines long-term success. A platform may function well independently, but if it complicates surrounding systems, efficiency declines.
Interoperability should be evaluated as carefully as feature functionality.
LIS and Enterprise System Alignment
Your LIS is the operational backbone of the lab. A digital pathology IMS must integrate seamlessly with it.
Key considerations include:
- Bi-directional data exchange in real-time
- Case status synchronization
- Integrated reporting workflows
- Aligned authentication and security
The objective isn’t to replace the technical side of your LIS, it is to provide a professional side workflow that is unique and specific to the ways pathologists work.
For larger organizations, alignment with enterprise IT standards (security, cloud policy, user management) also becomes critical.
Scanner Flexibility and Vendor Neutrality
Scanner selection often comes before IMS selection, but the two are closely linked.
Key questions to consider:
- Does the digital pathology IMS support multiple scanner types?
- Are we tied to a single hardware ecosystem?
- How easily can we add scanners or new sites?
Vendor neutrality reduces long-term dependency and gives labs flexibility as technology evolves. It also protects against being locked into a hardware-software pairing that may not meet future needs.
Preparing for Renewal or Expansion
Digital pathology contracts often span multiple years. During that time, labs may:
- Expand to additional sites
- Add subspecialty services to their test menus
- Integrate AI tools
- Increase case volume significantly
When evaluating a digital pathology IMS, consider how easily the system can adapt without major reconfiguration or replacement.
A flexible architecture reduces risk — not only at implementation, but at renewal and expansion.
Total Cost of Ownership Over 3–5 Years
Upfront pricing is only one part of the equation. For growing labs, the more important question is how a digital pathology IMS impacts cost structure over time.
A platform that appears less expensive at purchase can become costly if it requires additional hiring, limits productivity, or needs to be replaced as the lab expands. Evaluating total cost of ownership over a three- to five-year horizon provides a clearer picture of financial impact.
Platform Fees vs Operational Impact
Annual platform fees are easy to quantify. Operational impact is not, but it often carries greater financial risk.
When evaluating a digital pathology IMS, consider:
- Does the system reduce manual coordination and rework?
- Does it improve turnaround time consistency?
- Does it increase efficiency?
- Does it reduce reliance on temporary staffing during peak periods?
A system that meaningfully improves throughput and stability may justify higher platform fees because it shifts the lab’s overall operating model.
Avoided Hiring and Efficiency Gains
Growth traditionally requires additional headcount. As case volumes increase, labs often add assistants, histotechs, or even pathologists to maintain turnaround time.
A scalable digital pathology IMS can change that dynamic.
If workflow optimization and assistive tools increase productivity across the team, labs may:
- Delay or avoid incremental hires
- Reduce reliance on locum or temporary coverage
- Reallocate staff to higher-value work
Even modest productivity gains, sustained over time, can offset a significant portion of platform investment.
Cost Per Case and Long-Term ROI
Ultimately, many labs measure performance in cost per case or cost per slide.
A digital pathology IMS should be evaluated based on how it influences:
- Throughput per pathologist
- Rework rates
- Second-read or send-out frequency
- Turnaround time stability
When infrastructure supports higher output without proportional increases in labor, cost per case decreases.
Over a three- to five-year period, the combination of productivity gains, avoided hiring, and operational efficiencies often has a greater financial impact than initial licensing cost alone.
Questions to Ask Before Selecting a Digital Pathology IMS
Demos highlight features. Contracts outline pricing. But long-term success depends on asking the right structural questions before you commit.
As you evaluate a digital pathology IMS, focus less on what it can do today, and more on how it performs under growth, complexity, and change.
What Happens If Volume Doubles?
Growth is rarely linear. A new partnership, expanded services, or broader outreach can rapidly increase case volume.
Ask:
- Can this infrastructure support higher volume without performance degradation?
- Does cost increase proportionally with cases?
- Will we need additional headcount just to maintain turnaround times?
- How does the system handle multi-site or distributed workflows?
A scalable digital pathology IMS should absorb volume growth without forcing major structural changes.
How Easily Can We Add AI?
Even if AI adoption is not immediate, most labs anticipate integrating assistive tools in the coming years.
Key questions include:
- Can we integrate multiple algorithms over time?
- Are we limited to a single embedded AI solution?
- How are updates, validation, and governance handled?
- Will adding AI require workflow redesign?
Future-ready architecture allows labs to introduce AI deliberately, without rebuilding their infrastructure.
Will We Outgrow This in 3 Years?
This may be the most important question.
Consider:
- Are we selecting this platform because it fits our current size — or our projected growth?
- Will expansion to new sites require reconfiguration or replacement?
- Does the system support additional service lines and subspecialty growth?
- What happens at contract renewal if our needs have evolved?
Replacing a digital pathology IMS is disruptive and costly. Selecting infrastructure built for your next stage of growth reduces the risk of replatforming within a few years.
The goal isn’t simply to go digital. It’s to choose a digital pathology IMS that remains aligned with your operational and strategic direction over time.
Choosing an IMS That Grows With You
Selecting a digital pathology IMS is not just a technical decision. It’s a strategic one.
The right platform should do more than enable digital sign-out today. It should support sustained growth, measurable productivity gains, and long-term operational efficiency. It should integrate cleanly with your existing systems, adapt as AI evolves, and scale without forcing structural changes every few years.
For growing labs, the real question isn’t whether a system works. It’s whether it will continue to perform as complexity increases.
When evaluating your options, prioritize the infrastructure that supports where your lab is headed – not just where it stands today.
